How old is Wegovy, and what's happened since it launched?

Where the science started: semaglutide's origins in diabetes research

Semaglutide was developed by Novo Nordisk as a GLP-1 receptor agonist, a medicine that mimics a gut hormone involved in appetite and blood-sugar regulation. Its first UK licence was for type 2 diabetes under the brand name Ozempic, well before Wegovy existed. The diabetes research gave scientists unusually detailed data on the molecule's tolerability across thousands of patients, which shaped how the weight-management dose escalation was later designed.

The STEP clinical trial programme, which would eventually support Wegovy's weight-loss approvals globally, began recruiting in 2018. STEP 1 (the cornerstone study) enrolled adults with obesity or overweight alongside at least one weight-related condition and followed them for 68 weeks. Results published in the New England Journal of Medicine in 2021 showed an average body-weight reduction of around 15% with semaglutide 2.4 mg, a figure that placed it well ahead of anything previously approved for weight management. That evidence became the foundation on which regulators assessed the medicine.

For a fuller picture of what the molecule is and how it works in the body, the semaglutide overview on our treatment pages covers the mechanism in plain terms.

When Wegovy was approved in the UK, and what changed after launch

The MHRA granted Wegovy its UK marketing authorisation for weight management in September 2023. NICE recommended it for NHS use later that year under Technology Appraisal 875, though with significant access conditions: use within a specialist weight management service, for a maximum of two years, and for adults meeting specific BMI and comorbidity thresholds. NHS waiting lists for those pathways have remained long in most areas.

Private prescribing began once supply allowed, and demand quickly outpaced stock. That supply pressure is part of why understanding the medicine's full history matters, a newer, heavily demanded treatment in a short supply chain is also a target for counterfeit sellers. The MHRA has warned repeatedly about fake weight-loss pens sold online; the guidance on safely obtaining Wegovy explains what to look for when verifying any online pharmacy.

April 2026 brought a meaningful update. The MHRA approved a dedicated single-dose 7.2 mg Wegovy pen (one weekly injection replacing the previous three-pen approach used at that dose) for adults with a BMI of 30 or above. Trials reported around 20.7% average weight loss at 7.2 mg over 72 weeks, narrowing the gap with tirzepatide's highest-dose results. The starting dose and titration schedule remain unchanged; 7.2 mg is reached only after working up through the lower rungs under clinical supervision.

The oral chapter: Wegovy tablets approved in June 2026

The most recent milestone in Wegovy's short UK life came on 11 June 2026, when the MHRA approved Wegovy tablets (oral semaglutide co-formulated with an absorption enhancer) as the first oral GLP-1 medicine licensed for weight management anywhere in Europe. The tablet schedule runs from 1.5 mg daily up to a 25 mg maintenance dose, taken first thing in the morning on an empty stomach with a small amount of plain water, waiting at least 30 minutes before food or other medicines. No refrigeration is needed, which for many people is a practical advantage: the blister pack sits on a shelf rather than the fridge door, ready alongside a morning routine.

The pivotal OASIS 4 trial (307 adults, 64 weeks) showed an average weight loss of around 13.6% versus 2.4% with placebo; among participants who adhered fully to treatment the figure was approximately 17%. For people established on the 2.4 mg weekly injection, a direct switch to 25 mg tablets is possible subject to a clinical assessment. The tablet licence does not currently qualify for NHS reimbursement (a NICE appraisal would be required first) so it is currently available through private prescription only.

Our Wegovy treatment page brings together the injection and tablet options in one place, including how the age of the evidence base compares across the two formats.

Age on paper versus maturity in practice, what to weigh up

Fewer than three years as a UK weight-loss licence is a short time. The semaglutide molecule itself has a longer track record, but the 2.4 mg and 7.2 mg weight-management doses are newer than the headlines sometimes imply. NICE recommends the injection for a maximum of two years under its NHS guidance, partly reflecting the duration of the trial evidence available at appraisal. Longer-term cardiovascular outcome data continue to accumulate, Wegovy also holds a UK authorisation for reducing major cardiovascular event risk in eligible adults, which adds to the post-approval evidence pool.

The question of how old a patient needs to be to use Wegovy is separate from the medicine's own age. Both are licensed for adults only; the minimum age requirements for Wegovy are covered in detail on a dedicated page, and if you are curious about how semaglutide's development timeline compares with that of other GLP-1 medicines, the semaglutide timeline page sets out the broader history.

Side effects, storage requirements and how the medicine is actually administered all feature in the guide to how Wegovy is taken, a practical companion to understanding the approval history. If you think you may be eligible and want a clinical view on which treatment suits your circumstances, check your eligibility with our prescribers, every consultation is reviewed the same day by a real clinician, not automated software.